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Interleukin-31 (IL-31) is a recently discovered cytokine 
expressed in many human tissues, and predominantly by 
activated CD4+ T cells. IL-31 signals through a hetero-
dimeric receptor consisting of IL-31 receptor alpha (IL-
31RA) and oncostatin M receptor beta (OSMR). Earlier 
studies have shown involvement of IL-31 and its receptor 
components IL-31RA and OSMR in atopic dermatitis, 
pruritus and Th2-weighted inflammation at the mRNA 
level. The aim of this study was to investigate IL-31 pro-
tein expression in skin of such conditions. Immunohisto-
chemical staining for IL-31, IL-31RA and OSMR was 
performed in formalin-fixed paraffin-embedded biopsy 
specimens. IL-31 expression was increased in the inflam-
matory infiltrates from skin biopsies taken from subjects 
with atopic dermatitis, compared with controls (p ≤ 0.05). 
IL-31, IL-31RA and OSMR protein immunoreactivity 
was not increased in biopsies from subjects with other 
Th2-weighted and pruritic skin diseases. Our results con-
firm, at the protein level, the relationship between IL-31 
expression and atopic dermatitis. Our results do not sup-
port a general relationship between expression of IL-31/
IL-31R and pruritic or Th2-mediated diseases. Key words: 
atopic dermatitis; IL-31; pruritus; Th2-inflammation.
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Interleukin-31 (IL-31) is a recently discovered four-helix 
bundle cytokine that is expressed in low abundance in 
many human tissues (1) and at relatively high levels by 
activated CD4+ T cells, in particular those cells skewed 
toward a Th2-phenotype. Furthermore, expression of 
IL-31 has been shown in human cultured mast cells in 
myeloproliferative disorders (2). It has been shown that 
staphylococcal enterotoxin B (SEB) upregulates IL-31 in 
peripheral blood mononuclear cells (3). Induction of IL-
31 mRNA expression has been shown by stimulation of 
histamine receptor 4 in combination with SEB (4). IL-31 
signals through a heterodimeric receptor consisting of IL-31 
receptor alpha (IL-31RA) and oncostatin M receptor beta 
(OSMR). Through the receptor complex, IL-31 induces the 
activation of various signaling molecules, including Jak-, 
STAT and PI-3 kinase signaling pathways (1, 5, 6). The re-
ceptor components IL-31RA and OSMR are co-expressed 
on keratinocytes and activated monocytes (1). Besides the 
skin, other tissues, such as testis, thymus, trachea, intestinal 
epithelial cells and dorsal root ganglia, show mRNA co-
expression for the receptor components (1, 3, 7, 8).
Atopic dermatitis (AD) is a chronic inflammatory skin 
disease that is associated with intense pruritus. The me-
chanisms underlying dermatitis and pruritus are complex 
and not fully understood (9, 10), but there is emerging 
evidence that IL-31 may play a role. Transgenic mice 
that overexpress IL-31 develop severe pruritus and skin 
lesions similar to AD (1). In an AD-like murine model 
(NC/Nga mice), high IL-31 mRNA expression is asso-
ciated with scratching behavior (11), while an anti-IL-31 
antibody reduces scratching behavior (12). IL-31 mRNA 
expression is increased in biopsies of human AD compa-
red with normal skin (13), and correlates with IL-4 and 
IL-13 mRNA expression. In humans, IL-31 serum levels 
are higher in AD compared with non-atopic healthy con-
trols, and correlate with disease activity (14). An IL-31 
gene haplotype may be linked to genetic susceptibility to 
non-atopic eczema in humans (15). Taken together, these 
data suggest that IL-31 and its receptor components IL-
31RA and OSMR are involved in AD, and may be func-
tionally related to pruritus and Th2-weighted inflamma-
tion. The relationship between IL-31 and Th1-weighted 
inflammation is less clear. IL-31 mRNA expression was 
not increased in psoriasis (16), but was upregulated in 
inflammatory bowel disease mucosa (8). It was reported 
that the Th1 cytokines tumor necrosis factor (TNF)-α and 
interferon (IFN)-γ upregulate IL-31, IL-31RA and OSMR 
mRNA expression in human cell lines (8). 
Most investigations of IL-31 and its receptor components 
have been done at the mRNA level. On the protein level, 
only IL-31RA expression has been studied (13). The ob-
jective of this study was to collect immunohistochemistry 
data on IL-31, IL-31RA and OSMR protein expression in 
different skin diseases and to explore a correlation with 
pruritus or with Th2-weighted inflammation. 
MATERIALS AND METHODS
Samples 
Following ethics committee approval, appropriate formalin-
fixed paraffin-embedded tissue samples were selected from 
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the archive of the dermatohistopathological laboratory of the 
Department of Dermatology. Samples were diagnostic biopsies 
taken before treatment. The histology of the different skin 
diseases studied showed the typical histologic features overall 
and the typical distribution of inflammatory infiltrate for the 
particular disease. Only samples with typical histological fin-
dings were included in the study.
We identified at least 5 appropriate samples of each skin 
disease from our archives (except for pruritus sine materia 
(n = 2); Sézary syndrome (n = 4)). 
We investigated samples of AD, alopecia areata, pruritus sine 
materia, mycosis fungoides (MF) and Sézary syndrome (SS), and 
classified them into groups with or without pruritus, with Th1- or 
Th2-weighted inflammation or without inflammation (Table I). 
Such a classification inherently carries problems by grouping to-
gether heterogeneous disease conditions (17–30). For AD, biopsies 
of fresh lesions from patients with the extrinsic type of AD were 
chosen. Since AD is characterized by an initial phase predominated 
by Th2 cytokines, we classified AD as Th2-weighted disease (17). 
Itch is commonly reported in psoriasis, while the association of 
itch with a particular clinical presentation of psoriasis is less well 
defined (19–21). As samples for psoriasis, we used biopsies from 
non-itching chronic plaque type psoriasis (psoriasis vulgaris) and 
itching inverse type psoriasis (psoriasis inversa). Prurigo nodula-
ris can be associated with atopy (23) and can be initiated by the 
scratching in AD (prurigo-type atopic dermatitis). For our investi-
gations, we selected only samples of patients without history of AD. 
Data on the Th1- or Th2-weighted inflammation in alopecia areata 
vary (24–28). In our study, we used samples of localized alopecia 
areata, which probably reflects a Th2-weighted inflammation (25). 
MF and SS are Th2-weighted cutaneous T-cell lymphomas (29). 
Whereas MF in the patch and plaque stage often presents without 
pruritus, SS presents with the hallmark of severe pruritus (30). The 
clinical history of our patients with MF was without pruritus, the 
patients with SS had severe pruritus.
As a control for non-itching skin with little or no inflam-
mation, we used perilesional skin collected from safety margin 
tumor resections with no detectable residual tumor. Samples 
were collected from patients with no history of itching and/or 
known inflammatory skin disease.
Immunohistochemistry
Immunohistochemistry was performed for IL-31, IL-31RA, 
OSMR, CD45RO and CD68 with the following antibodies: 
monoclonal IgG1 mouse antibody specifically binding human 
IL-31 (MAB28241 clone 308202; R&D Systems Europe Ltd., 
Abingdon, UK), polyclonal rabbit antibody specifically binding 
human IL-31RA (Lot # E6292; ZymoGenetics Inc., Seattle, 
USA), polyclonal IgG rabbit antibody specifically binding 
human OSMR (10982-1-AP; ProteinTech, Chicago, USA), 
monoclonal IgG2a mouse antibody specifically binding human 
CD45RO (M0742, clone UCHL1; Dako, Glostrup, Denmark), 
monoclonal IgG1 mouse antibody specifically binding human 
CD68 (M0814, clone KP1; Dako, Glostrup, Denmark).
Adjacent sections of tissue 3–5 µm thickness were used for 
immunohistochemistry. For antigen retrieval, treatment condi-
tions for deparaffinized sections were adapted for each antibody. 
M0742: no antigen retrieval necessary. M0814: incubation with 
proteinase K solution (Dako, Glostrup, Denmark) 10 min at 
room temperature. MAB28241: heating in a pressure cooker 
for 15 min in 1 mM EDTA – buffer concentrate (Biocyc GmbH, 
Luckenwalde, Germany). E6292: heating in a pressure cooker 
for 15 min in citrate buffer (Target Retrieval Solution pH 9; 
Dako, Glostrup, Denmark). 10982-1-AP: heating in a pressure 
cooker for 15 min in citrate buffer (Target Retrieval Solution pH 
6; Dako, Glostrup, Denmark). The primary antibody was then 
incubated at room temperature (M0742 dilution 1:20 for 30 min, 
M0814 dilution 1:200 for 30 min, MAB28241 dilution 1:6 for 
30 min, E6292 dilution 1:1000 for 60 min, 10982-1-AP dilution 
1:50 for 60 min). Secondary staining was performed using the 
alkaline phosphatase anti-alkaline phosphatase method (31). 
Slides were counterstained with hemalaun solution. Fibroblasts, 
as well as other cells of the subcutaneous tissue, served as in-
ternal negative controls; appropriate external positive controls 
were used as recommended by the manufacturer. 
Epidermis and dermis of all samples were examined for immuno-
reactive cells by two independent examiners. Our investigations 
focused on the classical location of inflammatory infiltrate in the dif-
ferent skin diseases. This differs from disease to disease, but typically, 
the upper dermis in the vicinity of the dermoepidermal junction was 
the anatomical location with the highest density of inflammatory 
cells. We counted cells with clearly positive immunoreactivity. Cells 
were rated as immunoreactive or not and counted per visual field 
in three areas of most distinct inflammation with highest density 
of inflammatory cells, using 40-fold magnification. The mean total 
number of cells investigated per visual field is displayed in Fig. S1 
(available from: http://www.medicaljournals.se/acta/content/?do
i=10.2340/00015555-1191) and ranges from 36 cells per visual 
field (samples of pruritus sine materia) to 220 cells per visual field 
(Sézary syndrome). The percentage of positive cells compared with 
total infiltrating cells was then calculated. For statistical analysis 
the mean of the findings in each sample was calculated. Statistical 
analysis was performed using Microsoft Excel 2003 and Graph 
PadPrism 5.01 (one-way analysis of variance (ANOVA) with post-hoc 
Bonferroni’s multiple comparison test). The results are represented 
with error bars indicating the standard errors of the mean (SEM). 
RESULTS
IL-31 immunoreactivity by inflammatory cells 
predominates in atopic dermatitis
Immunoreactivity for IL-31 was present in 41 out of 
all 47 samples (87%) in cells of the dermal infiltrate 
in a predominantly cytoplasmatic pattern (Fig. 1), in 
contrast to the epidermal cells where reliable immu-
noreactivity of cells was not found. Cytokine staining 
in general is difficult, often leading to rather high 
background staining. In our experiments, background 
staining was seen especially in stainings with the IL-31 
antibody, despite optimized antigen retrieval, blocking, 
incubation and concentration of the antibody. The 
inflammatory infiltrate in samples of atopic dermatitis 
showed the highest number of positively stained cells 
Table I. Schematic classification of skin conditions examined according to their inflammatory profile and pruritus
No inflammation Th1-weighted inflammation Th2-weighted inflammation
No pruritus Perilesional skin (n = 5) Psoriasis vulgaris (n = 5) Mycosis fungoides (n = 5)
Alopecia areata (n = 5)
Pruritus Pruritus sine materia (n = 2)
Notalgia paresthetica (n = 5)
Prurigo nodularis (n = 5)
Psoriasis inversa (n = 6)
Atopic dermatitis (n = 5)
Sézary syndrome (n = 4)
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for IL-31. ANOVA with post-hoc Bonferroni’s multiple 
comparison test showed increased expression of IL-31 
in the infiltrate of atopic dermatitis compared with pe-
rilesional skin (p < 0.05; 95% confidence interval (CI): 
0.12–24.43), psoriasis (p < 0.01; 95% CI: 2.62–23.35), 
alopecia areata (p < 0.05; 95% CI: 1.18–25.48), MF 
(p < 0.01; 95% CI: 3.93–28.23), prurigo nodularis 
(p < 0.01; 95% CI: 4.22–28.53), notalgia paresthetica 
(p < 0.01; 95% CI: 5.19–29.5) and SS (p < 0.001; 95% 
CI: 6.13–31.91) (Fig. 2a). For pruritus sine materia, no 
differences were found compared with AD (p > 0.05; 
95% CI: –4.39–27.77) (Fig. 2a). 
Comparisons with all examined itching skin diseases 
showed increased IL-31 immunoreactivity only for AD 
(AD vs. pruritus sine materia p > 0.05; vs. psoriasis in-
versa p < 0.01, 95% CI: 2.86–23.11; vs. prurigo nodularis 
p < 0.01, 95% CI: 4.5–28.25; vs. nostalgia p < 0.01, 95% 
CI: 5.47–29.22; vs. Sézary syndrome p < 0.01, 95% CI: 
6.43–31.62). Similar results were found when comparing 
different Th2-weighted skin diseases(AD vs. alopecia 
areata p < 0.01, 95% CI: 2.81–23.84; vs. MF p < 0.01, 95% 
CI: 5.65–26.59; vs. SS p < 0.001, 95% CI 7.87–30.17).
IL-31RA and oncostatin M receptor beta immuno-
reactivity occurs in the dermal infiltrate of all samples
Immunoreactivity stainings for IL-31RA and OSMR 
yielded a predominantly cytoplasmatic staining pattern. 
Comparisons by ANOVA showed no difference in the 
expression of IL-31RA p = 0.13) and OSMR (p = 0.72) 
in the dermal infiltrate of investigated skin diseases 
(Figs 2 b and c).
Antigen retrieval and incubation conditions for the 
primary antibody (duration, temperature, concentration) 
were permutated. Epidermal staining for IL-31RA and 
OSMR yielded a moderate homogenous immunoreac-
tivity of keratinocytes in all samples analyzed. Staining 
intensity, however, did not vary much between disease 
conditions. A grading of immunoreactivity was thus not 
performed (data not shown).
Similar CD68 and CD45R0 immunoreactivity in the 
dermal infiltrate of the different skin diseases 
Except for Sézary syndrome, which is characterized 
by a distinct increase of cells in the dermal infiltrate, 
statistical analyses showed no differences for the total 
cell number in the dermal infiltrate of different skin 
diseases (Figs S1a, S2a, S3a (available from: http://
www.medicaljournals.se/acta/content/?doi=10.234
0/00015555-1191). Immunohistochemical stainings 
for CD68 and CD45RO as markers for macrophages/
dendritic cells and activated T lymphocytes, respec-
tively, showed positive results in all diseases. Statis-
tical analyses by ANOVA showed no differences in 
the expression rate of these markers in different skin 
diseases (Figs S1b, c, S2b, c, S3b, c (available from: 
http://www.medicaljournals.se/acta/content/?doi=10.2
340/00015555-1191). 
DISCUSSION
Earlier studies suggest that IL-31 and its receptor com-
ponents IL-31RA and OSMR are involved in AD (1, 
3, 4, 13, 14, 16), other itching dermatoses (3, 16) and 
Th2-weighted inflammation (1, 4, 16).
Our investigations showed increased immunoreacti-
vity of IL-31 in infiltrating cells in AD compared with 
other skin diseases. This supports earlier findings based 
on mRNA expression and supports a postulated role 
of IL-31 in AD (3, 13, 16). In the epidermis, moderate 
homogenous immunoreactivity could be detected in all 
samples for receptor components IL-31RA and OSMR. 
This emphasizes a constitutive expression of the recep-
tor components in keratinocytes, as has been shown in 
earlier investigations (1, 13). In infiltrating cells in the 
dermis, we found a mean of < 5% immunoreactivity for 
IL-31RA and OSMR in all skin diseases. The immuno-
reactivity in the dermal infiltrate mainly reflects the 
Fig. 1. Exemplary immunoreactivity results for: (b, e) interleukin (IL)-31, (c, f) 
IL-31RA, and (d, g) oncostatin M receptor beta (OSMR) immunohistochemistry 
of infiltrating inflammatory cells in atopic dermatitis skin biopsy specimens. 
Hematoxylin and eosin (H&E) staining of atopic dermatitis (a). Left row (b–d) 
shows immunopositive infiltrating cells, right row (e–g) shows immunonegative 
cells (internal negative controls) for the respective targets. 
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presence of macrophages, which have been shown to 
express the receptor components (1, 13). For IL-31RA, 
four splice variants have been described (1). With the 
antibody used, splice variants cannot be distinguished. 
Even though we found only low numbers of cells with 
positive immunoreactivity for the receptor components 
in the dermal infiltrate, it is important to mention that 
different receptor splice variants might be associated 
with differential function in different skin diseases.
Samples from subjects with AD were distinguish-
ed by increased IL-31 immunoreactivity compared 
with samples from other Th2-weighted skin diseases. 
Acute AD shows an increased number of Th2 cytoki-
nes compared with uninvolved or normal skin, while 
in a later and more chronic stage of AD, Th1-weighted 
inflammation dominates (17). Dillon et al. (1) reported 
RNA expression of IL-31 in both Th2 and Th1 T cells, 
though higher levels of IL-31 mRNA were observed in 
Th2 cells. Our results suggest that IL-31 is not so much 
involved in Th2-weighted-inflammation in general, but 
may rather play a role unique to AD. Investigations in 
mice, using an anti-IL-31-antibody, showed an initial 
reduction of scratching behavior waning over time (12). 
The authors explained their finding as possibly related 
to a transition from an acute Th2 dominant phase to 
a chronic state where Th1 inflammation plays a more 
dominant role, and suggested that IL-31 may be more 
important during the Th2-weighted stage of AD. Serial 
investigations on the same patient at different stages of 
disease may help to further characterize the impact of 
IL-31 in AD evolution.
There are many open questions in the pathogenesis of 
pruritus. Pruritus-modulators such as nerve growth factor 
and semaphorin, receptors such as µ opiate or Mrgpr 
receptors and pathways vary among pruritic diseases and 
are targets of current investigations (10, 32, 33). Pruritus-
mediators activate unmyelinated afferent neurons that 
originate as free nerve endings in the epidermis (34). IL-
31 has been suggested to be a key player in the develop-
ment of pruritus (1, 2, 13). It is unknown whether IL-31 
acts directly via its receptor on sensory nerve endings or 
indirectly, for example via keratinocytes. IL-31RA and 
OSMR were found in afferent cutaneous nerve fibers/
dorsal root ganglia (3, 7, 35); thus, IL-31 may be a link 
between the immune and the neural system. 
Our investigations for expression of neurons in the 
epidermis did not show differences in itchy dermatoses 
(immunohistochemical stainings for PGP9.5, data not 
shown). Increased peripheral sensory neurons have been 
reported in AD and prurigo nodularis. We believe that 
our biopsies were taken from earlier and subtle lesions, 
which, at this point in time, already display changes 
for IL31 expression, while not yet having had time to 
induce nerve sprouting visibly. Unlike our findings, 
Sonkoly et al. (3) have reported increased IL-31 mRNA 
expression in prurigo nodularis as well in patients with 
a history of atopy. The difference may be explained by 
technique, the small number of individuals studied, the 
stage of disease, or disease heterogeneity. For this study, 
we chose samples with typical clinical and histological 
findings while excluding an additional history of AD 
(prurigo type AD). Furthermore, we analyzed protein 
rather than mRNA expression. 
Our findings that samples from subjects with pso-
riasis showed no increased IL-31 immunoreactivity 
correspond with earlier findings based on mRNA ex-
pression (3, 16). In the group of psoriasis samples, 
we separately analyzed samples of psoriasis inversa, 
a variant of psoriasis that is often accompanied by 
itching. This subgroup did not show increased IL-31 
immunoreactivity, supporting our other findings that 
increased IL-31 expression is not a general feature of 
itching skin disease.
We found no differences in the expression rate of 
CD68 and CD45RO in different skin diseases and samp-
les from perilesional skin. We interpret these findings, 
first of all, as a result of having examined samples of 
very early inflammatory cell infiltrates, because these 
clinically earlier lesions are probably the ones that will 
be biopsied most for diagnostic purposes. Skin samples 
from perilesional skin are not the same as normal skin, 
and inflammatory cells can be found, first of all because 
of ongoing wound repair resulting from the primary 
tumor resection.
Our study is limited by its retrospective nature and a 
limited number of samples for each skin condition. How-
ever, the scope of diagnoses covered allows a broader 
overview of IL-31 involvement in itching and Th2-
weighted diseases than has been reported previously. To 
conclude, our data point to a role of IL-31 preferential in 
AD distinct from other Th2-weighted or other itching skin 
diseases. Follow-up studies will be based on fresh tissue 
in order to allow a wider range of antigens to be detected 
and to isolate cells for flow cytometry analysis. 
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Fig. 2. Percentage of dermal cells immunoreactive for (a) interleukin (IL)-31, (b) IL-31RA and (c) oncostatin M receptor beta (OSMR) in different skin diseases 
overall. Asterisks indicate differences between atopic dermatitis and the other skin diseases (*p < 0.05,**p < 0.01, ***p <0.001). Error bars indicate SEM. 
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IL-31 Expression by Inflammatory Cells is Preferen-
tially Elevated in Atopic Dermatitis 
In 2004, interleukin-31 (IL-31) was described as a 
short-chain 4-helix bundle cytokine that is expressed 
by activated CD4+ T cells, preferentially by T cells 
skewed toward a TH2 phenotype (1). Recently it has 
been demonstrated that human mast cells (MC) are also 
a source of IL-31 (2). Moreover, monocytes, macropha-
ges, immature and especially mature monocyte-derived 
dendritic cells produce IL-31 in response to ultraviolet 
(UV) irradiation and hydrogen peroxide (H2O2) treat-
ment (3). Low IL-31 mRNA expression levels have 
been detected in tissues from testis, bone marrow, ske-
letal muscle, kidney, colon, thymus, small intestine and 
trachea (1). In normal human epidermal keratinocytes 
and dermal fibroblasts-enhanced IL31 mRNA expres-
sion is measured upon H2O2 stimulation (3). In the skin 
of NC/Nga mice with scratching behaviour, an animal 
model of atopic dermatitis (AD), expression of IL-31 
mRNA was significantly higher than that in NC/Nga 
mice without scratching behaviour. Together, these fin-
dings suggest that IL-31 is associated with TH2-driven 
pruritic skin diseases, and that IL-31 may participate 
in the cause for itch sensation (4, 5). 
IL-31 signals through a heteromeric receptor complex 
composed of the IL-31 receptor alpha (IL-31RA) and 
the oncostatin M receptor beta (OSMR) subunits. Enga-
gement of the receptor complex results in activation of 
Janus kinase (JAK) tyrosine kinases and subsequently 
of different signalling molecules, including different 
signal transducers and activators of transcription (STAT) 
factors, as well as the MAPK and PI3K signalling 
pathways (Fig. 1). These pathways are activated in va-
rious cell types, including lung epithelial or malignant 
melanoma cells (6–8).
Expression of IL-31Rα and OSMRβ mRNA can be 
induced in activated monocytes, while their expression 
is constitutive in skin, testis and thymus, arguing that 
these organs are probably responsive to IL-31 (1, 9, 10). 
IL-31RA and OSMRβ are also found co-expressed in 
a subset of neurons of murine and human dorsal root 
ganglia (9, 11), which represents the site where the soma 
of cutaneous sensory neurons are located, while their 
sensory fibres protrude directly into the skin. These 
sensory neurons might be implicated in the sensing 
Fig. 1. Cytokine interleukin-31 (IL-31)-dependent signal transduction. (A) The IL-31 receptor is composed of IL-31 receptor alpha (IL-31RA) and oncostatin 
M receptor beta (OSMR). The domain structure of the two receptor subunits is indicated. Both have a C-terminal signalling peptide that is cleaved off during 
biosynthesis and translocation of the protein into the endoplasmic reticulum. IL-31 binds first to the IL-31RA (through two fibronectin III-like domains) and 
subsequently to the OSMR (through two fibronectin III-like and an immunoglobulin-like domain). Amino acids demonstrated to be important for binding 
are indicated; for binding to IL-31RA E44, E106, and H110; for binding to OSMR K134. The tyrosine residues that are phosphorylated by JAK kinases and 
mediate signalling are indicated. (B) Different cell types produce IL-31, as indicated; in many situations IL-31 production is regulated by different stimuli, 
including allergens, superantigens, and cytokines. The signalling that is stimulated is the JAK-STAT, the MAPK (i.e. ERK, p38 and JNK kinases), and the 
PI3K-AKT pathways. Of note is that IL-31RA activates predominantly different signal transducers and activators of transcription (STAT) molecules (purple), 
whereas OSMR is capable of stimulating all three pathways (green). These control downstream effectors, including transcriptional regulators that mediate 
and control IL-31-dependent target gene expression. 
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of itch and are possibly stimulated by IL-31. Recent 
studies demonstrated variations of IL-31RA expres-
sion in normal human epidermal keratinocytes that 
are dependent on the status of cellular differentiation 
and influenced by pro-inflammatory cytokines such as 
interferon-gamma (8). 
While enhanced IL-31 mRNA expression has pre-
viously been detected in skin samples of inflammatory 
skin diseases such as AD, allergic contact dermatitis or 
prurigo nodularis (9, 12, 13), hardly anything is known 
about the protein expression of this cytokine in lesional 
skin from patients with inflammatory skin diseases. This 
question has now been addressed in an article in this 
issue of Acta Dermato-Venereologica by Nobbe and 
colleagues (p. 24–28) (14).
In their study they performed immunohistochemical 
staining for IL-31, IL-31RA and OSMR in formalin-
fixed paraffin-embedded biopsy specimens of TH1- and 
TH2-weighted, pruritic and non-pruritic skin diseases. 
The authors demonstrate an enhanced IL-31 expres-
sion in biopsies of fresh lesions from patients with the 
extrinsic type of AD compared with controls. In 87% 
of samples from patients with AD cytoplasmic immu-
noreactivity for IL-31 was present in cells infiltrating 
the dermis, in contrast to epidermal cells, in which no 
significant staining could be detected (14). Comparisons 
of immunoreactivity in the dermal infiltrate of the exa-
mined itching skin diseases (AD, pruritus sine materia, 
psoriasis inverse, prurigo nodularis, Sézary syndrome, 
notalgia paraesthetica) revealed increased IL-31 immu-
noreactivity only in AD. Similar results were obtained 
by comparing different TH2-weighted diseases (AD, 
localized alopecia areata, mycosis fungoides, Sézary 
syndrome), showing increased IL-31 immunoreactivity 
only in samples from subjects with AD.
These studies confirm, at the protein level, the re-
lationship between IL-31 expression and AD that was 
previously identified at the mRNA level. However, the 
presented data do not support a general relationship 
between IL-31 protein expression and pruritic or TH2-
mediated diseases (14). Therefore IL-31 might play a 
role in the pathogenesis of AD and presents a putative 
therapeutic target, especially in the acute phase of this 
disease.
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